{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:09:45Z","timestamp":1787170185815,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Shaanxi Social Development Fund","award":["2020SF-067"],"award-info":[{"award-number":["2020SF-067"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11033-022-07713-6","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T07:03:17Z","timestamp":1660287797000},"page":"11403-11408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["CRISPR\/dCas9 for hepatic fibrosis therapy: implications and challenges"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-0238","authenticated-orcid":false,"given":"Nianan","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"7713_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hep.32285","volume":"75","author":"SL Friedman","year":"2022","unstructured":"Friedman SL, Pinzani M (2022) Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology 75:473\u2013488","journal-title":"Hepatology"},{"key":"7713_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S2468-1253(18)30339-X","volume":"4","author":"JA Flemming","year":"2019","unstructured":"Flemming JA, Dewit Y, Mah JM, Saperia J, Groome PA, Booth CM (2019) Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol 4:217\u2013226","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7713_CR3","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1002\/jmv.24894","volume":"89","author":"J Lu","year":"2017","unstructured":"Lu J, Xiang X, Cao Z, Wang W, Zhao G, Tang W, Chen L, Guo S, Zhuang Y, Shi D, Chen L, Bao S, Cai W, Wang H, Zhou H, Xie Q (2017) Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China. J Med Virol 89:1973\u20131980","journal-title":"J Med Virol"},{"key":"7713_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jhep.2021.09.032","volume":"76","author":"J Qing","year":"2022","unstructured":"Qing J, Ren Y, Zhang Y, Yan M, Zhang H, Wu D, Ma Y, Chen Y, Huang X, Wu Q, Mazhar M, Wang L, Liu J, Ding BS, Cao Z (2022) Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis. J Hepatol 76:394\u2013406","journal-title":"J Hepatol"},{"key":"7713_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","volume":"76","author":"F Foerster","year":"2022","unstructured":"Foerster F, Gairing SJ, Muller L, Galle PR (2022) NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 76:446\u2013457","journal-title":"J Hepatol"},{"key":"7713_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jconrel.2021.11.033","volume":"341","author":"Q Lu","year":"2022","unstructured":"Lu Q, Zhou Y, Xu M, Liang X, Jing H, Wang X, Li N (2022) Sequential delivery for hepatic fibrosis treatment based on carvedilol loaded star-like nanozyme. J Control Release 341:247\u2013260","journal-title":"J Control Release"},{"key":"7713_CR7","doi-asserted-by":"crossref","unstructured":"Roehlen N, Crouchet E, Baumert TF (2020) Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 9","DOI":"10.3390\/cells9040875"},{"key":"7713_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41575-020-0342-4","volume":"18","author":"GK Michalopoulos","year":"2021","unstructured":"Michalopoulos GK, Bhushan B (2021) Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol 18:40\u201355","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7713_CR9","doi-asserted-by":"crossref","unstructured":"Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F (2021) Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. Cells. 10","DOI":"10.3390\/cells10102759"},{"key":"7713_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D (2021) Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 18:151\u2013166","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7713_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota S, Raguram A, Suh S, Du SW, Davis JR, Choi EH, Wang X, Nielsen SC, Newby GA, Randolph PB, Osborn MJ, Musunuru K, Palczewski K, Liu DR (2022) Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185:250\u2013265 e216","journal-title":"Cell"},{"key":"7713_CR12","first-page":"242","volume":"16","author":"H Wood","year":"2020","unstructured":"Wood H (2020) Gene therapy boosts response to levodopa in patients with Parkinson disease. Nat Rev Neurol 16:242","journal-title":"Nat Rev Neurol"},{"key":"7713_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41417-021-00340-6","volume":"29","author":"G Giamas","year":"2022","unstructured":"Giamas G, Gagliano T (2022) Cancer gene therapy 2020: highlights from a challenging year. Cancer Gene Ther 29:1\u20133","journal-title":"Cancer Gene Ther"},{"key":"7713_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/nar\/gkab1197","volume":"50","author":"X Wang","year":"2022","unstructured":"Wang X, Li X, Ma Y, He J, Liu X, Yu G, Yin H, Zhang H (2022) Inhibition mechanisms of CRISPR-Cas9 by AcrIIA17 and AcrIIA18. Nucleic Acids Res 50:512\u2013521","journal-title":"Nucleic Acids Res"},{"key":"7713_CR15","doi-asserted-by":"publisher","first-page":"121327","DOI":"10.1016\/j.biomaterials.2021.121327","volume":"281","author":"H Park","year":"2022","unstructured":"Park H, Kim D, Cho B, Byun J, Kim YS, Ahn Y, Hur J, Oh YK, Kim J (2022) In vivo therapeutic genome editing via CRISPR\/Cas9 magnetoplexes for myocardial infarction. Biomaterials 281:121327","journal-title":"Biomaterials"},{"key":"7713_CR16","doi-asserted-by":"crossref","unstructured":"Lin-Shiao E, Pfeifer WG, Shy BR, Saffari Doost M, Chen E, Vykunta VS, Hamilton JR, Stahl EC, Lopez DM, Sandoval Espinoza CR, Deyanov AE, Lew RJ, Poirer MG, Marson A, Castro CE, Doudna JA (2022) CRISPR-Cas9-mediated nuclear transport and genomic integration of nanostructured genes in human primary cells.Nucleic Acids Res","DOI":"10.1101\/2021.11.08.467750"},{"key":"7713_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1039\/D1BM01716K","volume":"10","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, Park JM, Lee S, Cho HB, Park JI, Kim JH, Park JS, Park KH (2022) Efficient CRISPR-Cas9-based knockdown of RUNX2 to induce chondrogenic differentiation of stem cells. Biomater Sci 10:514\u2013523","journal-title":"Biomater Sci"},{"key":"7713_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","volume":"152","author":"LS Qi","year":"2013","unstructured":"Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173\u20131183","journal-title":"Cell"},{"key":"7713_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14136","volume":"517","author":"S Konermann","year":"2015","unstructured":"Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517:583\u2013588","journal-title":"Nature"},{"key":"7713_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nmeth.2598","volume":"10","author":"ML Maeder","year":"2013","unstructured":"Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10:977\u2013979","journal-title":"Nat Methods"},{"key":"7713_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nmeth.3312","volume":"12","author":"A Chavez","year":"2015","unstructured":"Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, R. I. E P, Lin S, Kiani S, Guzman CD, Wiegand DJ, Ter-Ovanesyan D, Braff JL, Davidsohn N, Housden BE, Perrimon N, Weiss R, Aach J, Collins JJ, Church GM (2015) Highly efficient Cas9-mediated transcriptional programming. Nat Methods 12:326\u2013328","journal-title":"Nat Methods"},{"key":"7713_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/0008-5472.CAN-21-1692","volume":"82","author":"L Jiang","year":"2022","unstructured":"Jiang L, Ingelshed K, Shen Y, Boddul SV, Iyer VS, Kasza Z, Sedimbi S, Lane DP, Wermeling F (2022) CRISPR\/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies. Cancer Res 82:36\u201345","journal-title":"Cancer Res"},{"key":"7713_CR23","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41467-022-28028-x","volume":"13","author":"R Fu","year":"2022","unstructured":"Fu R, He W, Dou J, Villarreal OD, Bedford E, Wang H, Hou C, Zhang L, Wang Y, Ma D, Chen Y, Gao X, Depken M, Xu H (2022) Systematic decomposition of sequence determinants governing CRISPR\/Cas9 specificity. Nat Commun 13:474","journal-title":"Nat Commun"},{"key":"7713_CR24","doi-asserted-by":"publisher","first-page":"114087","DOI":"10.1016\/j.addr.2021.114087","volume":"181","author":"H Bloomer","year":"2022","unstructured":"Bloomer H, Khirallah J, Li Y, Xu Q (2022) CRISPR\/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells. Adv Drug Deliv Rev 181:114087","journal-title":"Adv Drug Deliv Rev"},{"key":"7713_CR25","doi-asserted-by":"crossref","unstructured":"Bhattacharjee G, Gohil N, Khambhati K, Mani I, Maurya R, Karapurkar JK, Gohil J, Chu DT, Vu-Thi H, Alzahrani KJ, Show PL, Rawal RM, Ramakrishna S, Singh V (2022) Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications.J Control Release","DOI":"10.1016\/j.jconrel.2022.02.005"},{"key":"7713_CR26","doi-asserted-by":"crossref","unstructured":"Balon K, Sheriff A, Jackow J, Laczmanski L (2022) Targeting Cancer with CRISPR\/Cas9-Based Therapy.Int J Mol Sci. 23","DOI":"10.3390\/ijms23010573"},{"key":"7713_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.7150\/thno.47007","volume":"11","author":"S Zhang","year":"2021","unstructured":"Zhang S, Shen J, Li D, Cheng Y (2021) Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing. Theranostics 11:614\u2013648","journal-title":"Theranostics"},{"key":"7713_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41375-020-01071-7","volume":"35","author":"I Tirado-Gonzalez","year":"2021","unstructured":"Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A, Soetopo D, Bergonzani E, Mahmoud A, Contreras A, Jeremias I, Platzbecker U, Bourquin JP, Kloz U, Van der Hoeven F, Medyouf H (2021) Correction: CRISPR\/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia 35:294","journal-title":"Leukemia"},{"key":"7713_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.omtm.2020.10.019","volume":"20","author":"A Kondrashov","year":"2021","unstructured":"Kondrashov A, Mohd Yusof NAN, Hasan A, Goulding J, Kodagoda T, Hoang DM, Vo NTN, Melarangi T, Dolatshad N, Gorelik J, Hill SJ, Harding SE, Denning C (2021) CRISPR\/Cas9-mediated generation and analysis of N terminus polymorphic models of beta2AR in isogenic hPSC-derived cardiomyocytes. Mol Ther Methods Clin Dev 20:39\u201353","journal-title":"Mol Ther Methods Clin Dev"},{"key":"7713_CR30","doi-asserted-by":"publisher","first-page":"e21205","DOI":"10.1096\/fj.202001745RR","volume":"35","author":"H You","year":"2021","unstructured":"You H, Mayer JU, Johnston RL, Sivakumaran H, Ranasinghe S, Rivera V, Kondrashova O, Koufariotis LT, Du X, Driguez P, French JD, Waddell N, Duke MG, Ittiprasert W, Mann VH, Brindley PJ, Jones MK, McManus DP (2021) CRISPR\/Cas9-mediated genome editing of Schistosoma mansoni acetylcholinesterase. FASEB J 35:e21205","journal-title":"FASEB J"},{"key":"7713_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.gde.2020.12.005","volume":"66","author":"L van der Weyden","year":"2021","unstructured":"van der Weyden L, Jonkers J, Adams DJ (2021) The use of CRISPR\/Cas9-based gene editing strategies to explore cancer gene function in mice. Curr Opin Genet Dev 66:57\u201362","journal-title":"Curr Opin Genet Dev"},{"key":"7713_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1021\/acs.nanolett.8b02689","volume":"19","author":"Z Li","year":"2019","unstructured":"Li Z, Zhou X, Wei M, Gao X, Zhao L, Shi R, Sun W, Duan Y, Yang G, Yuan L (2019) In Vitro and in Vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated with miRNA or CRISPR\/dCas9. Nano Lett 19:19\u201328","journal-title":"Nano Lett"},{"key":"7713_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jhepr.2019.09.002","volume":"1","author":"M Alves-Bezerra","year":"2019","unstructured":"Alves-Bezerra M, Furey N, Johnson CG, Bissig KD (2019) Using CRISPR\/Cas9 to model human liver disease. JHEP Rep 1:392\u2013402","journal-title":"JHEP Rep"},{"key":"7713_CR34","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.ymthe.2018.02.023","volume":"26","author":"K Singh","year":"2018","unstructured":"Singh K, Evens H, Nair N, Rincon MY, Sarcar S, Samara-Kuko E, Chuah MK, VandenDriessche T (2018) Efficient In Vivo Liver-Directed Gene Editing Using CRISPR\/Cas9. Mol Ther 26:1241\u20131254","journal-title":"Mol Ther"},{"key":"7713_CR35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41397-020-0160-7","volume":"20","author":"Y Wei","year":"2020","unstructured":"Wei Y, Huai C, Zhou C, Gao Y, Chen L, Zhou W, Wei M, Qin S (2020) A methylation functional detection hepatic cell system validates correlation between DNA methylation and drug-induced liver injury. Pharmacogenomics J 20:717\u2013723","journal-title":"Pharmacogenomics J"},{"key":"7713_CR36","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1038\/s41467-020-17818-w","volume":"11","author":"Q Xu","year":"2020","unstructured":"Xu Q, Li Y, Gao X, Kang K, Williams JG, Tong L, Liu J, Ji M, Deterding LJ, Tong X, Locasale JW, Li L, Shats I, Li X (2020) HNF4alpha regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer. Nat Commun 11:3978","journal-title":"Nat Commun"},{"key":"7713_CR37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/gut.2008.174904","volume":"59","author":"HY Yue","year":"2010","unstructured":"Yue HY, Yin C, Hou JL, Zeng X, Chen YX, Zhong W, Hu PF, Deng X, Tan YX, Zhang JP, Ning BF, Shi J, Zhang X, Wang HY, Lin Y, Xie WF (2010) Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut 59:236\u2013246","journal-title":"Gut"},{"key":"7713_CR38","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jhep.2021.08.011","volume":"75","author":"T Yang","year":"2021","unstructured":"Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, Song G, Yuan Q, Yao Q, Shen X, Taubert R, Engel B, Jaeckel E, Vogel A, Falk CS, Schambach A, Gerovska D, Arauzo-Bravo MJ, Vondran FWR, Cantz T, Horscroft N, Balakrishnan A, Chevessier F, Ott M, Sharma AD (2021) Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol 75:1420\u20131433","journal-title":"J Hepatol"},{"key":"7713_CR39","doi-asserted-by":"publisher","first-page":"e0221085","DOI":"10.1371\/journal.pone.0221085","volume":"14","author":"MR Park","year":"2019","unstructured":"Park MR, Wong MS, Arauzo-Bravo MJ, Lee H, Nam D, Park SY, Seo HD, Lee SM, Zeilhofer HF, Zaehres H, Scholer HR, Kim JB (2019) Oct4 and Hnf4alpha-induced hepatic stem cells ameliorate chronic liver injury in liver fibrosis model. PLoS ONE 14:e0221085","journal-title":"PLoS ONE"},{"key":"7713_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/10717544.2020.1850917","volume":"28","author":"N Luo","year":"2021","unstructured":"Luo N, Li J, Chen Y, Xu Y, Wei Y, Lu J, Dong R (2021) Hepatic stellate cell reprogramming via exosome-mediated CRISPR\/dCas9-VP64 delivery. Drug Deliv 28:10\u201318","journal-title":"Drug Deliv"},{"key":"7713_CR41","doi-asserted-by":"publisher","first-page":"15532","DOI":"10.1038\/s41598-017-15831-6","volume":"7","author":"W Wang","year":"2017","unstructured":"Wang W, Yao LJ, Shen W, Ding K, Shi PM, Chen F, He J, Ding J, Zhang X, Xie WF (2017) FOXA2 alleviates CCl4-induced liver fibrosis by protecting hepatocytes in mice. Sci Rep 7:15532","journal-title":"Sci Rep"},{"key":"7713_CR42","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2174\/1568009619666190326130008","volume":"19","author":"JW Wright","year":"2019","unstructured":"Wright JW, Church KJ, Harding JW (2019) Hepatocyte Growth Factor and Macrophage-stimulating Protein \u201cHinge\u201d Analogs to Treat Pancreatic Cancer. Curr Cancer Drug Targets 19:782\u2013795","journal-title":"Curr Cancer Drug Targets"},{"key":"7713_CR43","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1021\/acssynbio.8b00192","volume":"7","author":"D Lainscek","year":"2018","unstructured":"Lainscek D, Kadunc L, Keber MM, Bratkovic IH, Romih R, Jerala R (2018) Delivery of an Artificial Transcription Regulator dCas9-VPR by Extracellular Vesicles for Therapeutic Gene Activation. ACS Synth Biol 7:2715\u20132725","journal-title":"ACS Synth Biol"},{"key":"7713_CR44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41556-020-0511-2","volume":"22","author":"F Li","year":"2020","unstructured":"Li F, Huangyang P, Burrows M, Guo K, Riscal R, Godfrey J, Lee KE, Lin N, Lee P, Blair IA, Keith B, Li B, Simon MC (2020) FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome. Nat Cell Biol 22:728\u2013739","journal-title":"Nat Cell Biol"},{"key":"7713_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13287-019-1539-8","volume":"11","author":"L Dong","year":"2020","unstructured":"Dong L, Pu Y, Chen X, Qi X, Zhang L, Xu L, Li W, Ma Y, Zhou S, Zhu J, Li Y, Wang X, Su C (2020) hUCMSC-extracellular vesicles downregulated hepatic stellate cell activation and reduced liver injury in S. japonicum-infected mice. Stem Cell Res Ther 11:21","journal-title":"Stem Cell Res Ther"},{"key":"7713_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jhep.2020.02.005","volume":"73","author":"JP Arab","year":"2020","unstructured":"Arab JP, Cabrera D, Sehrawat TS, Jalan-Sakrikar N, Verma VK, Simonetto D, Cao S, Yaqoob U, Leon J, Freire M, Vargas JI, De Assuncao TM, Kwon JH, Guo Y, Kostallari E, Cai Q, Kisseleva T, Oh Y, Arrese M, Huebert RC, Shah VH (2020) Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12. J Hepatol 73:149\u2013160","journal-title":"J Hepatol"},{"key":"7713_CR47","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1136\/gutjnl-2018-317872","volume":"68","author":"L Tao","year":"2019","unstructured":"Tao L, Ma W, Wu L, Xu M, Yang Y, Zhang W, Sha W, Li H, Xu J, Feng R, Xue D, Zhang J, Dooley S, Seki E, Liu P, Liu C (2019) Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5\/Smad signalling. Gut 68:2214\u20132227","journal-title":"Gut"},{"key":"7713_CR48","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/hep.30677","volume":"70","author":"C DeRossi","year":"2019","unstructured":"DeRossi C, Bambino K, Morrison J, Sakarin I, Villacorta-Martin C, Zhang C, Ellis JL, Fiel MI, Ybanez M, Lee YA, Huang KL, Yin C, Sakaguchi TF, Friedman SL, Villanueva A, Chu J (2019) Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. Hepatology 70:2107\u20132122","journal-title":"Hepatology"},{"key":"7713_CR49","doi-asserted-by":"publisher","first-page":"114042","DOI":"10.1016\/j.addr.2021.114042","volume":"180","author":"J Yan","year":"2022","unstructured":"Yan J, Kang DD, Turnbull G, Dong Y (2022) Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer. Adv Drug Deliv Rev 180:114042","journal-title":"Adv Drug Deliv Rev"},{"key":"7713_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12951-021-01233-4","volume":"20","author":"D Wang","year":"2022","unstructured":"Wang D, Chen L, Li C, Long Q, Yang Q, Huang A, Tang H (2022) CRISPR\/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy. J Nanobiotechnol 20:27","journal-title":"J Nanobiotechnol"},{"key":"7713_CR51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ymthe.2021.06.003","volume":"30","author":"M van Hees","year":"2022","unstructured":"van Hees M, Slott S, Hansen AH, Kim HS, Ji HP, Astakhova K (2022) New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape. Mol Ther 30:32\u201346","journal-title":"Mol Ther"},{"key":"7713_CR52","doi-asserted-by":"publisher","first-page":"118969","DOI":"10.1016\/j.lfs.2020.118969","volume":"267","author":"A Ghaemi","year":"2021","unstructured":"Ghaemi A, Bagheri E, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M (2021) CRISPR-cas9 genome editing delivery systems for targeted cancer therapy. Life Sci 267:118969","journal-title":"Life Sci"},{"key":"7713_CR53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","volume":"171","author":"L Li","year":"2018","unstructured":"Li L, Hu S, Chen X (2018) Non-viral delivery systems for CRISPR\/Cas9-based genome editing: Challenges and opportunities. Biomaterials 171:207\u2013218","journal-title":"Biomaterials"},{"key":"7713_CR54","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.tibtech.2017.11.006","volume":"36","author":"Z Glass","year":"2018","unstructured":"Glass Z, Lee M, Li Y, Xu Q (2018) Engineering the Delivery System for CRISPR-Based Genome Editing. Trends Biotechnol 36:173\u2013185","journal-title":"Trends Biotechnol"},{"key":"7713_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2019.01.017","volume":"447","author":"M Chen","year":"2019","unstructured":"Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J (2019) CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Cancer Lett 447:48\u201355","journal-title":"Cancer Lett"},{"key":"7713_CR56","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","volume":"181","author":"D Wang","year":"2020","unstructured":"Wang D, Zhang F, Gao G (2020) CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors. Cell 181:136\u2013150","journal-title":"Cell"},{"key":"7713_CR57","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12033-020-00258-8","volume":"62","author":"Z Liu","year":"2020","unstructured":"Liu Z, Liao Z, Chen Y, Han L, Yin Q, Xiao H (2020) Application of Various Delivery Methods for CRISPR\/dCas9. Mol Biotechnol 62:355\u2013363","journal-title":"Mol Biotechnol"},{"key":"7713_CR58","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jconrel.2022.01.045","volume":"343","author":"DS Manickam","year":"2022","unstructured":"Manickam DS (2022) Delivery of mitochondria via extracellular vesicles - A new horizon in drug delivery. J Control Release 343:400\u2013407","journal-title":"J Control Release"},{"key":"7713_CR59","doi-asserted-by":"crossref","unstructured":"Chen R, Huang H, Liu H, Xi J, Ning J, Zeng W, Shen C, Zhang T, Yu G, Xu Q, Chen X, Wang J, Lu F (2019) Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein. Small. 15: e1902686","DOI":"10.1002\/smll.201902686"},{"key":"7713_CR60","doi-asserted-by":"publisher","first-page":"1700611","DOI":"10.1002\/advs.201700611","volume":"5","author":"Y Lin","year":"2018","unstructured":"Lin Y, Wu J, Gu W, Huang Y, Tong Z, Huang L, Tan J (2018) Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR\/Cas9 System in MSCs. Adv Sci (Weinh) 5:1700611","journal-title":"Adv Sci (Weinh)"},{"key":"7713_CR61","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1093\/nar\/gky1165","volume":"47","author":"CC Shen","year":"2019","unstructured":"Shen CC, Hsu MN, Chang CW, Lin MW, Hwu JR, Tu Y, Hu YC (2019) Synthetic switch to minimize CRISPR off-target effects by self-restricting Cas9 transcription and translation. Nucleic Acids Res 47:e13","journal-title":"Nucleic Acids Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07713-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-07713-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07713-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T17:25:36Z","timestamp":1669829136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-07713-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7713"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-07713-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"7 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All the authors approved the present version for publication purposes and agreed to hold accountability for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}